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Abstract Transition from hormone-sensitive to hormone-
refractory metastatic tumor types poses a major challenge
for prostate cancer treatment. Tumor antigens that are
differentially expressed during this transition are likely to
play important roles in imparting prostate cancer cells with
the ability to grow in a hormone-deprived environment and
to metastasize to distal sites such as the bone and thus, are
likely targets for therapeutic intervention. To identify those
molecules and particularly cell surface antigens that
accompany this transition, we studied the changes in cell
surface antigenic profiles between a hormone-sensitive
prostate cancer line LNCaP and its hormone-refractory
derivative C4-2B, using an antibody library-based affinity
proteomic approach. We selected a naïve phage antibody
display library to identify human single-chain antibodies
that bind specifically to C4-2B but not LNCaP. Using mass
spectrometry, we identified one of the antibody-targeted
antigens as the ICAM-1/CD54/human rhinovirus receptor.
Recombinant IgG1 derived from this single-chain antibody
binds to a neutralizing epitope of ICAM-1 and blocks C4-2B
cell invasion through extracellular matrix in vitro. ICAM-1 is
thus differentially expressed during the transition of the
hormone-sensitive prostate cancer cell line LNCaP to its
hormone-refractory derivative C4-2B, plays an important
role in imparting the C4-2B line with the ability to invade,
and may therefore be a target for therapeutic intervention.
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Abbreviations
FACS fluorescence activated cell sorting
ICAM-1 intercellular adhesion molecule 1
mAb monoclonal antibody
LC-MS/MS liquid chromatography–tandem mass
spectrometry
CHO Chinese hamster ovary
SA-PE streptavidin-phycoerythrin
mAb monoclonal antibody
FBS fetal bovine serum
MFI mean fluorescence intensity
Introduction
A major challenge of prostate cancer treatment is the transi-
tion from a hormone-sensitive localized form of the disease
to a hormone-refractory metastatic tumor. Bone is one of
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the most common sites for prostate cancer metastasis [1, 2].
The exact reason for this bone-tropism is under active in-
vestigation and several molecules/pathways have been
identified as involved in this process [3–8]. Despite this
progress, a complete understanding of this behavior of
prostate cancer cells is lacking.
We sought to identify cell surface antigens differentially
expressed by a hormone-refractory metastatic prostate
cancer cell line but not by an isotype-matched hormone-
sensitive line with less metastatic potential. We hypothe-
sized that those differentially expressed cell surface
antigens may impart prostate cancer cells with the ability
to thrive in a hormone-deprived environment and to
colonize at distal organ sites such as the bone and may
thus be targets for therapeutic intervention. As a model
system for the transition, we studied the hormone-sensitive
prostate cancer line LNCaP that does not metastasize to the
bone and its hormone-refractory derivative C4-2B that
metastasizes to the bone. The C4-2B line was derived from
LNCaP following serial passages in vivo and selective
recovery of cells from the bone [9, 10] and has been widely
used to study hormone-sensitivity/refractory status and
bone tropism of prostate cancer [8, 10–12].
We have previously developed and utilized a naïve
phage antibody display library to identify internalizing
human single-chain antibodies targeting several solid
human tumors including prostate tumors [13–21]. We
report in this study the use of the phage antibody display
approach to probe the altered cell surface epitope space
associated with the metastatic, hormone-refractory C4-2B
line. We identified a panel of human scFvs that bind
preferentially to the C4-2B cell line but not the parental
LNCaP line, suggesting that a molecular signature exists
that accompanies the transition of prostate cancer cells from
a hormone-sensitive to a hormone-refractory bone meta-
static form, and that this signature can be identified by our
antibody library-based approach. Using mass spectrometric
analysis, we identified ICAM-1/CD54/human rhinovirus
receptor precursor as the target antigen of one of our C4-
2B-targeting scFvs. We have further demonstrated that this
antibody binds to a neutralizing epitope of ICAM-1 and
that a human IgG1 derived from this scFv effectively
blocks prostate cancer invasions in vitro through extracel-
lular matrix components.
Materials and methods
Reagents For scFv and IgG purification and characteriza-
tion: CHO-S-SFM II media and G418 (Invitrogen, Carlsbad,
CA, USA), 1 L spinner flask (Corning, Corning, NY, USA),
CellgroTM Stirrers (Barnstead, Dubuque, IA, USA),
HisTrapTMHP, HiTrap protein A HP and HiTrap desalting
columns (GE Healthcare, Piscataway, NJ, USA). For FACS:
streptavidin-phycoerythrin (SA-PE) (Invitrogen/BioSource,
Camarillo, CA, USA), PE-conjugated anti-human Fc-
specific mAb (Jackson ImmunoResearch, West Grove, PA,
USA), murine anti-ICAM-1 mAb (clone BBIG-l1) (R&D
System, Minneapolis, MN, USA), and biotin-labeled rabbit
anti-fd bacteriophage (Sigma-Aldrich, St. Louis, MO, USA).
For immunoprecipitation: mammalian protease inhibitor
cocktails (Sigma-Aldrich), NP40 and protein A agarose
beads (Pierce, Rockford, IL, USA). For cell invasion assay:
Matrigel Basement Membrane Mix (BD Biosciences, San
Jose, CA, USA), Transwell (CorningCostar, Corning, NY,
USA), and Diff-Quik (Dade Behring Inc, Newark, DE,
USA).
Cell lines LNCaP was purchased from American Type
Culture Collection (ATCC) and C4-2B from DIANON/
Urocor (Oklahoma City, OK, USA). The CHO-ICAM-1
line, a stably transfected CHO cell line expressing the full-
length human ICAM-1 protein, was purchased from the
ATCC. The CHO DG44 cell line (dhfr-) was purchased
from Invitrogen. The BPH-1 line was originally obtained
from Dr. Gerald Cunha [22] at UCSF and maintained in
the lab.
Selection of C4-2B-specific phage antibodies For counter-
selection, a naïve library containing 500 million members
was incubated with LNCaP cells at 4°C for 8 h, centrifuged
to collect the supernatants, and the counter-selected library
was further incubated with C4-2B cells at 37°C for 2 h. The
cells were then washed three times with ice-cold RPMI
media containing 0.5% fetal bovine serum (FBS), once with
100 mM glycine containing 150 mM NaCl, pH 2.8, and
once with phosphate-buffered saline (PBS), and lysed with
300 µl 100 mM triethylamine at RT for 5 min, neutralized
with 150 µl 1 M Tris–HCl, and used to infect exponentially
growing TG1 bacteria. The infected TG1 were plated on
LB-agar plates containing tetracycline (50 µg/ml) and
incubated at 37°C overnight. Colonies on the plate were
scraped off and used to inoculate 2× YT media containing
tetracycline (50 µg/ml) at 37°C for 12 h, the supernatants
were collected by centrifugation and phage prepared by
polyethylene glycol precipitation as described [16–18]. The
polyclonal phage antibodies were used as the input for the
next round of selection using the same counter-selection
then selection procedure described above.
Analysis of binding phage antibodies FACS was used to
screen for monoclonal phage antibodies that bind specifi-
cally to C4-2B but not LNCaP. Phage-infected bacteria
grown on agar plates were picked into 96-well U bottom
culture plates in 2× YT media containing tetracycline
(50 µg/ml) and grown overnight at 37°C. After centrifuga-
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tion, an identical amount of supernatants (50 µl per well per
plate) containing phage particles were transferred into two
V-bottom plates, and incubated with LNCaP and C4-2B
cells, respectively, at RT for 1 h. Following washing with
PBS, bound phage were detected by biotin-labeled anti-fd
antibodies followed by streptavidin-phycoerythrin (SA-PE),
using FACS LSRII (BD Biosciences, San Jose, CA, USA)
as described [17, 18].
Recombinant human IgG1 The development of recombi-
nant IgG1 from scFv has been described previously [23].
We have previously constructed a mammalian expression
vector that produces recombinant fully human M10A12
IgG1 using genetic information of the M10A12 scFv [23].
CHO DG44 cells stably transfected with the M10A12
IgG1-expressing plasmid were grown in CHO-S-SFM II
containing G418 in 1 L spinner flasks on CellgroTMStirrers
as described [23]. Supernatants were collected and purified
on a HiTrap Protein A column using an AKTAprime (GE
Healthcare).
Identification of the target antigen as ICAM-1/CD54/
rhinovirus receptor We used the M10A12 IgG1 to immu-
noprecipitate the target antigen from C4-2B lysates, and
analyzed the product by tandem mass spectrometry. Ten
million tumor cells were harvested, washed, and pelleted in
an Eppendorf microcentrifuge tube. Cell pellets were
resuspended in cell lysis buffer (1% NP-40 in PBS,
pH 7.2, with mammalian protease inhibitor cocktails added
at v/v 1:200 per manufacturer’s instruction) and incubated
on ice for 1 h. Following centrifugation in an Eppendorf
5417R at 10,000×g for 15 min, the supernatants were
collected, pre-cleared by incubating with protein A beads
on ice for 4 h, centrifuged at 10,000×g at 4°C for 15 min
to remove the beads, divided into two parts, and further
incubated with the M10A12 IgG1 and a control non-
binding human IgG1 respectively on ice for 4 h. Immuno-
precipitation products of both the M10A12 IgG1 and the
control IgG1 were analyzed on a gradient SDS-PAGE gel
(4–20%, Invitrogen), stained with coomassie blue and
bands unique to the M10A12 IgG immunoprecipitation
products were excised, digested with trypsin, and analyzed
by liquid chromatography–tandem mass spectrometry (LC-
MS/MS). Peptides were separated by reverse phase chro-
matography using an Ultimate HPLC (Dionex) and then
analyzed on-line using a QSTAR Pulsar Mass Spectrometer
(MDS Sciex/Applied Biosystems). Raw data was converted
to peaklists using the Mascot dll in Analyst (version
1.6b16), then searched using Batch-Tag in Protein Pros-
pector (version 5.0) [24] against mammalian proteins in the
SwissProt Database (downloaded June 2008: 52,897 entries
searched), allowing a precursor mass accuracy tolerance of
50 ppm and a fragment mass tolerance of 0.1 Da.
Acceptance criteria was a peptide expectation value of less
than 0.05. To confirm the identification, CHO (control) and
CHO cells stably transfected with the full-length human
ICAM-1 gene were incubated with the M10A12 IgG1 at RT
for 30 min, washed three times with PBS/0.5% FBS, further
incubated with PE-conjugated anti-human Fc antibodies, and
then analyzed by FACS. As a further control for background
staining, the experiment was repeated using a recombinant
anti-botulinum toxin human IgG1, CR-2, which does not
bind to prostate cancer cells.
Cell invasion assay MatriGel basement membrane was used
as the matrix for the cell invasion assay. About 2.5×105 cells
were mixed with 50 µg/ml IgGs at 37°C for 1 h. In the
meantime, MatriGel was dissolved in RPMI media at 4°C
and placed on the top chamber (insert) at 37°C to solidify.
The cells were placed on top of the MatriGel layer and
incubated for 48 h. Cells remaining in the top layer of the
chamber were removed. After Diff-Quik staining, viable
cells that migrated to the lower layer of the chamber were
counted under an inverted microscope (Nikon, Japan). The
experiments were performed in triplicate and the data were
analyzed using a student t test. A p value of less than 0.05
was used as indication of a significant difference.
Results
Selection of scFvs that bind specifically to C4-2B but not
the parental LNCaP line We first counter-selected a 500
million-member naïve phage antibody library on the
parental LNCaP cells and then incubated the counter-
selected library with the C4-2B cells. After three rounds
of counter-selection and selection, we arrayed the output
phage antibodies into 96-well plates, collected the super-
natants containing monoclonal phage antibodies, and
screened for phage antibodies that bind to C4-2B (target)
but not LNCaP (control) cells. An example of specific
binding phage is shown in Fig. 1. An anti-CD26 mAb was
used as a positive control, as CD26 has been shown to be
preferentially expressed by C4-2B cells by microarray
analysis [8]. We identified a large number of phage
antibodies that bound preferentially to C4-2B but not
LNCaP (Fig. 2). Phage antibodies that showed specific
binding to C4-2B cells were sequenced. Thirty-two unique
phage antibodies were identified after screening about 400
clones from the output of the third round of selection. One
of the scFvs was identical in sequence to the M10A12 scFv
that we previously identified as binding to an unknown
antigen expressed by prostate cancer lines PC3 and Du-145
[23]. For uniformity, in subsequent studies we will use the
original name M10A12 to refer this scFv.
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Identification of ICAM-1 as a C4-2B-associated cell surface
antigen We sought to identify the target antigen bound by the
M10A12 antibody. We have previously converted the
M10A12 scFv into a full-length human IgG1 [23]. We used
the recombinant M10A12 IgG1 to immunoprecipitate prostate
cancer cell lysates and analyzed the immunoprecipitation
products by mass spectrometry. LC-MS/MS analysis identi-
fied two peptides that matched perfectly with human ICAM-1,
also known as CD54 or human rhinovirus receptor, and an
example of one of these matches is shown in Fig. 3. To
confirm this identification, we studied binding patterns of the
M10A12 IgG1 to CHO (control) and CHO cells stably
transfected with a full-length human ICAM-1 cDNA. We
found that the M10A12 antibody bound specifically to CHO-
ICAM-1 but not CHO (Figs. 4a, b), further confirming that
ICAM-1 is the target of the M10A12 antibody.
TheM10A12 IgG1 binds to a neutralizing epitope of ICAM-1 To
further study the ICAM-1 epitope bound by the M10A12
antibody, we performed a competition assay using a murine
Fig. 1 Selection of C4-2B-specific scFvs from a phage antibody display library. Binding of a selected phage antibody (scFv1) and an anti-CD26
mAb (control) to C4-2B and LNCaP cells was analyzed by FACS. Histogram plots of FACS binding data are shown
Fig. 2 Binding patterns of 32
selected phage antibodies that
bind preferentially to C4-2B but
not LNCaP. Ctr control, cells
stained with a control non-
binding phage antibody; MFI
mean fluorescence intensity. The
experiment was done in tripli-
cate and error bars indicate
standard deviations
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Fig. 3 Mass spectrometric iden-
tification of M10A12 immuno-
precipitated product as ICAM-1.
Two peptides were matched
with high confidence to
ICAM-1 (accession number
P05362), one of which is the
peptide spanning residues
57–66, which was matched with
an expectation value of being
incorrect of 7.1×10−4
Fig. 4 M10A12 IgG1 binds
specifically to CHO cells stably
expressing human ICAM-1.
a Histograms of M10A12 IgG1
binding to CHO (control) and
CHO-ICAM-1 cells. b MFI
values are plotted. Control IgG a
control non-binding human
IgG1 (CR-2). An axis (y) break
is used and the graph is not
drawn to scale
J Mol Med (2009) 87:507–514 511
neutralizing anti-ICAM-1 mAb (clone BBIG-I1). This murine
mAb targets an ICAM-1 epitope that is involved in ligand
binding [25–27]. We found that this neutralizing murine mAb
competed with the M10A12 IgG1 for binding to C4-2B cells
(Figs. 5a, b), suggesting that the M10A12 IgG1 and the mu-
rine mAb bind to the same neutralizing epitope of ICAM-1.
The M10A12 IgG1 blocks C4-2B cell invasion through
extracellular matrix components To study the functional
consequences of antibody binding to this neutralizing
ICAM-1 epitope, we performed an in vitro invasion assay
using the C4-2B cells and studied if binding by the M10A12
IgG1 effectively blocks invasion of C4-2B cells through
extracellular matrix components using the MatriGel-based in
vitro invasion assay. C4-2B and LNCaP cells showed
markedly different invasion ability through MatriGel
(Fig. 6a). Interestingly, we found that the M10A12 IgG1
caused a significant inhibition of C4-2B invasion through
MatriGel while the control IgG1 did not (Fig. 6b). The
M10A12 IgG1 did not significantly affect the residual level
Fig. 5 The M10A12 IgG1 binds to a neutralizing epitope of ICAM-1.
a Histograms of M10A12 IgG1 binding to C4-2B in the presence or
absence of the competing murine neutralizing anti-ICAM-1 mAb
(clone BBIG-l1). b MFI values are plotted for the competition
experiment. The experiment was done in triplicate. Error bars indicate
standard deviations. Control secondary antibodies only
Fig. 6 Inhibition of C4-2B invasion through MatriGel in vitro by the
M10A12 neutralizing anti-ICAM-1 human IgG1. a C4-2B has higher
intrinsic invasion ability than LNCaP. The experiment was done in
triplicate. P<0.05 indicates significant difference between C4-2B and
LNCaP. b Inhibition of C4-2B invasion by M10A12 IgG1. A non-
binding human IgG1 (CR-2) was used as control. The experiment was
done in triplicates and the P<0.05 indicates a significant difference
between M10A12- and control CR-2-treated C4-2B cells. There are no
significant differences between M10A12- and CR-2-treated LNCaP
cells, consistent with a lack of ICAM-1 expression by LNCaP cells
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of invasion activity of LNCaP (Fig. 6b), consistent with the
lack of binding of M10A12 IgG1 by LNCaP cells.
Discussion
To search for molecules that are selectively expressed during
transition of prostate cancer cells from being hormone-
sensitive to hormone-refractory with enhanced metastatic
potential, we have taken an antibody library approach to
identify cell surface differences between two isotype-
matched prostate cancer cell lines, the parental hormone
sensitive LNCaP line and its hormone refractory bone-
metastasizing derivative C4-2B. This model system has been
widely used by investigators to study prostate cancer
development, affording an opportunity to identify meaning-
ful cell surface changes accompanying prostate tumor
progression. We have identified 32 unique human scFvs that
bind selectively to C4-2B but not LNCaP cells. We have
found that one of the C4-2B-targeting scFvs is identical in
sequence to a previously identified scFv, M10A12. We used
a full-length human IgG1 developed from the M10A12 scFv
to immunoprecipitate tumor antigens from prostate cancer
cell lysates and used mass spectrometric analysis to identify
the target antigen as ICAM-1, also known as CD54 or human
rhinovirus receptor. Furthermore, through a competition
study with a known neutralizing murine mAb targeting
human ICAM-1, we found that the M10A12 IgG1 binds to
the same neutralizing epitope and inhibits invasion of the
C4-2B cells through extracellular matrix. Taken together,
these studies demonstrate that ICAM-1 is differentially
expressed during the transition from the parental LNCaP
cells to hormone refractory bone-metastasizing C4-2B cells
and may play important roles in mediating prostate cancer
invasion and metastasis.
Human ICAM gene family members have been impli-
cated in prostate development and progression by genetic
studies. A large genome-wide association study identified a
loci on chromosome 19 that is associated with predisposi-
tion to breast and prostate cancer [28]. By high-density
single nucleotide polymorphism mapping, the extent of
association was found to span 20 kb and include the ICAM-1
gene and two other genes in the ICAM family [28]. A
genome-wide characterization of gene expression variations
and DNA copy number changes in prostate cancer cell lines
also found that ICAM-1 is associated with an enhanced
malignant potential [29]. Despite this genetic evidence and
gene expression studies, exactly how ICAM-1 mediates
prostate cancer progression remains undetermined. Our
study suggests that ICAM-1 mediates invasive behavior of
prostate cancer cells, and thus is likely to play an important
role in tumor metastasis to distal sites.
We have developed a full-length human neutralizing mAb
(M10A12 IgG1) that blocks C4-2B invasion through extracel-
lular matrix components, making this antibody a potential
candidate for therapeutic development. However, further
studies are needed to evaluate if this neutralizing anti-ICAM-
1 human IgG1 can block prostate cancer cell metastasis in vivo.
While we have demonstrated that ICAM-1 is differentially
expressed by C4-2B cells and plays a key role in mediating
invasion through extracellular matrix by these cells, we have
not directly studied if ICAM-1 expression is sufficient to
allow the hormone sensitive LNCaP cells to achieve hormone
independence and metastasize to the bone. It also remains to
be determined if ICAM-1 expression is necessary for C4-2B
cells to maintain hormone independence and propensity to
localize to the bone. Further studies with appropriate prostate
cancer animal models are needed to address these issues.
ICAM-1 is also known as the receptor for human rhinovirus,
a causative agent for the common cold. In addition, ICAM-1 is a
part of the receptor complex for other Picornavirus family
members such as the Coxsackievirus A21. Recently, researchers
have exploited ICAM-1 expression on prostate cancer cell lines
to achieve efficient infection by oncolytic viruses and observed
potent tumor cell killing in vitro [30]. It would be interesting to
see if oncolytic viruses can be developed into therapeutic
agents to effectively kill in vivo metastatic hormone-refractory
prostate tumors that express ICAM-1.
To summarize, our antibody library-based approach is
effective in identifying antibodies targeting cell surface
molecules that are functionally important for prostate
cancer progression. These tumor-targeting scFvs and their
derivatives such as IgGs are human in sequence, providing
a direct route to the clinic. ICAM-1 has been identified as
a cell surface antigen that is differentially expressed in
the hormone-refractory metastatic prostate cancer cell line
C4-2B, and a fully human neutralizing IgG1 blocks C4-2B
invasion through extracellular matrix. In addition to ICAM-1,
other antigens defined by this panel of scFvs remain to be
identified. Using mass spectrometric analysis described in
this report and other novel expression cloning strategies
described elsewhere [31, 32], we are identifying additional
antigens that play important roles in mediating various
functions in advanced prostate tumors including hormone-
independence and the propensity to metastasize to the bone
and other distal sites.
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